1-7 of 7
Daniel Afar
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Elotuzumab (HuLuc63) Activates CD56 dim Natural Killer Cells and Monocytes Resulting in the Release of IP-10 and MCP-1

Free
Balaji Balasa, PhD, Mahrukh Huseni, MSc, Jyothi Cherukuri, MSc, Roxanne Steinle, BSc, Amulya Nanisetti, MSc, Daniel Afar, PhD, Eric Hsi, MD, Vladimir Vexler, PhD
Journal: Blood
Blood (2008) 112 (11): 108.
https://doi.org/10.1182/blood.V112.11.108.108
Published: 2008
Journal Articles

CS1 Promotes Multiple Myeloma Cell Adhesion, Clonogenic Growth, and Tumorigenicity Via C-Maf-Mediated Interactions with Bone Marrow Stromal Cells (BMSCs)

Free
Yu-Tzu Tai, PhD, Ender Soydan, Mariateresa Fulciniti, Weihua Song, Xian-Feng Li, Peter Burger, Fangxin Hong, Giovanni Tonon, Kihyun Kim, Mathew J. Rumizen, Sabikun Nahar, Klaus Podar, Dharminder Chauhan, Teru Hideshima, Daniel R. Carrasco, Nikhil C Munshi, Daniel Afar, PhD, Kenneth C. Anderson
Journal: Blood
Blood (2008) 112 (11): 840.
https://doi.org/10.1182/blood.V112.11.840.840
Published: 2008
Journal Articles

Ex Vivo Activated Natural Killer (NK) Cells from Myeloma Patients Kill Autologous Myeloma and Killing Is Enhanced by Elotuzumab

Free
Tarun K. Garg, PhD, Susann Szmania, BS, Jumei Shi, MD, PhD, Katie Stone, BS, Amberly Moreno-Bost, BS, Paul Malbrough, BS, Dario Campana, MD., PhD, Bart Barlogie, MD, PhD, Daniel Afar, PhD, Frits van Rhee, MD, PhD
Journal: Blood
Blood (2008) 112 (11): 3666.
https://doi.org/10.1182/blood.V112.11.3666.3666
Published: 2008
Journal Articles

Eradication of Tumors in Pre-Clinical Models of Multiple Myeloma by Anti-CS1 Monoclonal Antibody HuLuc63: Mechanism of Action Studies.

Free
Audie Rice, PhD, Myles Dillon, B.S., Anne van Abbema, M.S., Lynne Jesaitis, Ph.D, Melanie Wong, M.Sc., Stacey Lawson, B.S., Gao Liu, M.S., Yin Zhang, M.S., David Powers, PhD, Susan Rhodes, B.Sc., Ingrid Caras, PhD, Debbie Law, PhD, Daniel Afar, PhD
Journal: Blood
Blood (2006) 108 (11): 3503.
https://doi.org/10.1182/blood.V108.11.3503.3503
Published: 2006
Journal Articles

CS1: A Potential New Therapeutic Target for the Treatment of Multiple Myeloma.

Free
Eric D. Hsi, MD, Roxanne Steinle, BA, Balaji Balasa, PhD, Aparna Draksharapu, MS, Benny Shum, MS, Marukh Huseni, BS, David Powers, PhD, Amulya Nanisetti, MS, Marna Williams, PhD, Vladimir Vexler, PhD, Mohamad Hussein, MD, Daniel Afar, PhD
Journal: Blood
Blood (2006) 108 (11): 3457.
https://doi.org/10.1182/blood.V108.11.3457.3457
Published: 2006
Journal Articles

Killing of Drug-Sensitive and Resistant Myeloma Cells and Disruption of Their Bone Marrow Stromal Interaction by HuLuc63, a Novel Humanized Anti-CS1 Monoclonal Antibody.

Free
Yu-Tzu Tai, PhD, Weihua Song, M.D., Xian-Feng Li, M.S., Peter Burger, B.S., Robert Schlossman, M.D., Audie Rice, Ph.D., Anne van Abbema, Ph.D., Paul Richardson, M.D., Nikhil C. Munshi, M.D., Daniel Afar, Ph.D., Kenneth C. Anderson, M.D.
Journal: Blood
Blood (2006) 108 (11): 3470.
https://doi.org/10.1182/blood.V108.11.3470.3470
Published: 2006
Journal Articles

CS1 Is Expressed on Myeloma Cells from Early Stage, Late Stage, and Drug-Treated Multiple Myeloma Patients, and Is Selectively Targeted by the HuLuc63 Antibody.

Free
Susann Szmania, BS, Balaji Balasa, PhD, Priyangi Malaviarachchi, BS, Fenguhuang Zhan, MD,PhD, Yongsheng Huang, MS, Aparna Draksharapu, MD, Vladimir Vexler, PhD, John Shaughnessy, Jr., PhD, Bart Barlogie, MD,PhD, Guido Tricot, MD,PhD, Daniel Afar, PhD, van Rhee Frits, MD,PhD
Journal: Blood
Blood (2006) 108 (11): 660.
https://doi.org/10.1182/blood.V108.11.660.660
Published: 2006